Alliancebernstein L.P. lowered its stake in Humana Inc. (NYSE:HUM - Free Report) by 58.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 151,095 shares of the insurance provider's stock after selling 210,262 shares during the quarter. Alliancebernstein L.P. owned 0.13% of Humana worth $38,334,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. FPC Investment Advisory Inc. acquired a new stake in Humana during the 4th quarter worth $27,000. Centricity Wealth Management LLC purchased a new stake in Humana during the fourth quarter worth about $30,000. LFA Lugano Financial Advisors SA grew its position in shares of Humana by 56.3% during the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock worth $32,000 after buying an additional 45 shares in the last quarter. OFI Invest Asset Management acquired a new position in Humana in the fourth quarter valued at approximately $33,000. Finally, Atwood & Palmer Inc. boosted its holdings in Humana by 64.5% in the fourth quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider's stock valued at $39,000 after purchasing an additional 60 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company's stock.
Analysts Set New Price Targets
A number of equities analysts recently issued reports on HUM shares. JPMorgan Chase & Co. lowered their price target on Humana from $257.00 to $256.00 and set a "neutral" rating for the company in a report on Tuesday, February 18th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $290.00 price objective on shares of Humana in a research note on Wednesday, February 12th. Piper Sandler upped their price target on Humana from $270.00 to $288.00 and gave the stock a "neutral" rating in a research note on Wednesday, January 15th. Royal Bank of Canada restated an "outperform" rating and set a $283.00 price target on shares of Humana in a research note on Wednesday, February 12th. Finally, Truist Financial upped their price target on Humana from $260.00 to $290.00 and gave the stock a "hold" rating in a research note on Monday, January 6th. Seventeen analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $284.25.
Check Out Our Latest Analysis on HUM
Humana Trading Up 1.3 %
Shares of Humana stock traded up $3.60 during trading hours on Thursday, reaching $289.13. The stock had a trading volume of 423,934 shares, compared to its average volume of 1,738,626. The firm has a 50 day simple moving average of $265.60 and a two-hundred day simple moving average of $270.92. The firm has a market capitalization of $34.90 billion, a price-to-earnings ratio of 29.02, a P/E/G ratio of 2.05 and a beta of 0.62. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. Humana Inc. has a 1 year low of $213.31 and a 1 year high of $406.46.
Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping analysts' consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. As a group, equities research analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current year.
Humana Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be issued a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, March 28th. This represents a $3.54 annualized dividend and a dividend yield of 1.22%. Humana's payout ratio is currently 35.58%.
About Humana
(
Free Report)
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
See Also
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
